| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5508 | Way-170523 | Potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3) |
|
| DCC5509 | Way-171230 | Inhibitor of matrix metalloproteinase-1 (MMP-1) |
|
| DCC5510 | Way-260022 | Potent and Selective Inhibitor of the Norepinephrine Transporter |
|
| DCC5511 | Way-316606 Hydrochloride | Secreted frizzled-related protein-1 (sFRP-1) modulaitor |
|
| DCC5512 | Wb-308 | Novel inhibitor of The epidermal growth factor receptor (EGFR), decreasing NSCLC cell proliferation and colony formation, by causing G2/M arrest and apoptosis. |
|
| DCC5513 | Wb4-24 | Non-peptide GLP-1 receptor agonist, blocking inflammatory nociception by stimulating β-endorphin release from spinal microglia |
|
| DCC5514 | Wck5153 | Novel Inhibitor of PBP2, Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones |
|
| DCC5515 | We-14 Tfa Salt | Highly conserved neuropeptide derived from Chromogranin A (Parathyroid Secretory Protein 1) |
|
| DCC5516 | Web2347 | Novel very potent and long acting hetrazepinoic PAF-antagonist |
|
| DCC5517 | Wen05-03 | Novel inhibitor of type III secretion system ATPase EscN from enteropathogenic Eecherichia coli |
|
| DCC5518 | Wfq-228 | Novel fluoroquinolone antibiotic with potent antimicrobial activity, showing the potential to overcome major drug resistance; its antimicrobial activity was less affected by both pump-mediated efflux and QRDR mutations in P. aeruginosa compared with LVX a |
|
| DCC5519 | Whz-04 | Novel Anti-malarial Plasmodium-Selective Proteasome Inhibitor |
|
| DCC5520 | Win-35428 | Dopamine reuptake inhibitor, also having some SERT affinity |
|
| DCC5521 | Win-64338 | B2 bradykinin receptor antagonist |
|
| DCC5522 | Withangulatin A | Natural potent antitumoragent, targeting sarco/endoplasmic reticulum calcium-ATPase (SERCA)2 |
|
| DCC5523 | Wj35435 | Novel dual inhibitor of histone deacetylase and topoisomerase I |
|
| DCC5524 | Wjd008 | Novel potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), preventing PI3K signaling and inhibiting the proliferation of transformed cells with oncogenic PI3K mutant |
|
| DCC5525 | Wms-1410 | Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sen |
|
| DCC5526 | Wms-2539 | Potent uncompetitive NMDA receptor antagonist |
|
| DCC5527 | Wn1316 | Unique neuroprotectant against oxidative injury, being a highly promising remedy for the treatment of amyotrophic lateral sclerosis (ALS) |
|
| DCC5528 | Wnk-in-3 | Novel Allosteric WNK Kinase Inhibitor |
|
| DCC5529 | Wnt/hh-in-1 | Novel potent dual inhibitor of Wnt and hedgehog signalings, blocking porcupine and smoothened |
|
| DCC5530 | Wny0824 | Novel dual BRD4 and PLK1 inhibitor (IC 50 values of 109 and 22 nM, respectively), showing strong antiproliferative activity against cancer cells |
|
| DCC5531 | Wo-459 | Novel GPR52 agonist, dose-dependently inducing elevation of intracellular cAMP in HEK293/GPR52 cells |
|
| DCC5532 | Wp1193 | Novel inhibitor of the JAK2/STAT3 pathway |
|
| DCC5533 | Wp-871 Monohydrate | Main active metabolite of tazanolast, inhibiting dose-dependently compound 48/80-induced histamine release from rat peritoneal mast cells |
|
| DCC5534 | Wqe-134 | Novel Dual Inhibitor of Nitric Oxide and Prostaglandin E2 Production |
|
| DCC5535 | Wr99210 | Potent inhibitor of Plasmodium falciparum dihydrofolate reductase (DHFR) |
|
| DCC5536 | Wrr-286 | Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.6 nM |
|
| DCC5537 | Wrr-391 | Novel potent inhibitor of Schistosoma mansoni cathepsin B1 (SmCB1) with IC50 ~0.2 nM |
|
